Abstract
Benign prostatic hyperplasia (BPH) and the related medical problems are a major burden as health care costs and as a cause of patient morbidity. The introduction of medical therapy largely offered an alternative to surgical therapy, and these medications have been linked with multiple positive BPH-related outcomes. With ubiquitous use, however, a variety of adverse side effects and unsupported claims to these medications have been reported both in scientific literature and popular press. The use of 5 alpha reductase inhibitors (5ARIs) to reduce recurrent bleeding due to BPH is a reasonable option for men with recurrent trips to the physician or hospital. After a largely anecdotal report of their use in the preoperative period to reduce bleeding during BPH surgery, there was interest in the use of 5ARIs for this indication considering the effusive bleeding that can occur during BPH-related surgery, a dreaded and not uncommon complication. While the pathophysiology for the use of 5ARI to reduce BPH-related bleeding is sound, the actual clinical outcomes still require scrutiny to determine if the efficacy is both scientifically valid and clinically significant. This report will review the current literature on this topic and make attempts to determine if the use of a 5ARI before BPH-related surgery should be encouraged.
Similar content being viewed by others
References
Papers of particular interest, published recently, have been highlighted as: • Of importance
American Urological Association. Management of Benign Prostatic Hyperplasia (BPH). 2014. http://www.auanet.org/guidelines/benign-prostatic-hyperplasia-(2010-reviewed-and-validity-confirmed-2014). Accessed 5 May 2017.
Welliver C, McVary KT. Minimally invasive and endoscopic management of benign prostatic hyperplasia. In: Wein AJ, Kavoussi LR, Partin AW, Peters CA, editors. Campbell-Walsh urology. 11th ed. Philadelphia, PA: Elsevier; 2015.
Hagerty JA, Ginsberg PC, Harmon JD, Harkaway RC. Pretreatment with finasteride decreases perioperative bleeding associated with transurethral resection of the prostate. Urology. 2000;55(5):684–9.
Foley SJ, Soloman LZ, Wedderburn AW, Kashif KM, Summerton D, Basketter V, et al. A prospective study of the natural history of hematuria associated with benign prostatic hyperplasia and the effect of finasteride. J Urol. 2000;163(2):496–8.
Roehrborn CG, McConnell JD, Lieber M, Kaplan S, Geller J, Malek GH, et al. Serum prostate-specific antigen concentration is a powerful predictor of acute urinary retention and need for surgery in men with clinical benign prostatic hyperplasia. PLESS Study Group. Urology. 1999;53(3):473–80.
Roehrborn CG, Bruskewitz R, Nickel JC, McConnell JD, Saltzman B, Gittelman MC, et al. Sustained decrease in incidence of acute urinary retention and surgery with finasteride for 6 years in men with benign prostatic hyperplasia. J Urol. 2004;171(3):1194–8. doi:10.1097/01.ju.0000112918.74410.94.
Fwu CW, Eggers PW, Kirkali Z, McVary KT, Burrows PK, Kusek JW. Change in sexual function in men with lower urinary tract symptoms/benign prostatic hyperplasia associated with long-term treatment with doxazosin, finasteride and combined therapy. J Urol. 2014;191(6):1828–34. doi:10.1016/j.juro.2013.12.014.
Welliver C, Butcher M, Potini Y, McVary KT. Impact of alpha blockers, 5-alpha reductase inhibitors and combination therapy on sexual function. Curr Urol Rep. 2014;15(10):441. doi:10.1007/s11934-014-0441-2.
Cunha GR, Chung LW, Shannon JM, Taguchi O, Fujii H. Hormone-induced morphogenesis and growth: role of mesenchymal-epithelial interactions. Recent Prog Horm Res. 1983;39:559–98.
Chung LW, Gleave ME, Hsieh JT, Hong SJ, Zhau HE. Reciprocal mesenchymal-epithelial interaction affecting prostate tumour growth and hormonal responsiveness. Cancer Surv. 1991;11:91–121.
Tanner MJ, Welliver RC Jr, Chen M, Shtutman M, Godoy A, Smith G, et al. Effects of androgen receptor and androgen on gene expression in prostate stromal fibroblasts and paracrine signaling to prostate cancer cells. PLoS One. 2011;6(1):e16027. doi:10.1371/journal.pone.0016027.
Ferrara N. Role of vascular endothelial growth factor in the regulation of angiogenesis. Kidney Int. 1999;56(3):794–814. doi:10.1046/j.1523-1755.1999.00610.x.
Ravindranath N, Wion D, Brachet P, Djakiew D. Epidermal growth factor modulates the expression of vascular endothelial growth factor in the human prostate. J Androl. 2001;22(3):432–43.
Latif F, Tory K, Gnarra J, Yao M, Duh FM, Orcutt ML, et al. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science. 1993;260(5112):1317–20.
Linehan WM, Pinto PA, Srinivasan R, Merino M, Choyke P, Choyke L, et al. Identification of the genes for kidney cancer: opportunity for disease-specific targeted therapeutics. Clin Cancer Res. 2007;13(2 Pt 2):671s–9s. doi:10.1158/1078-0432.CCR-06-1870.
Joseph IB, Nelson JB, Denmeade SR, Isaacs JT. Androgens regulate vascular endothelial growth factor content in normal and malignant prostatic tissue. Clin Cancer Res. 1997;3(12 Pt 1):2507–11.
Sordello S, Bertrand N, Plouet J. Vascular endothelial growth factor is up-regulated in vitro and in vivo by androgens. Biochem Biophys Res Commun. 1998;251(1):287–90. doi:10.1006/bbrc.1998.9328.
Aslan G, Cimen S, Yorukoglu K, Tuna B, Sonmez D, Mungan U, et al. Vascular endothelial growth factor expression in untreated and androgen-deprived patients with prostate cancer. Pathol Res Pract. 2005;201(8–9):593–8. doi:10.1016/j.prp.2005.07.003.
Kravchick S, Cytron S, Mamonov A, Peled R, Linov L. Effect of short-term dutasteride therapy on prostate vascularity in patients with benign prostatic hyperplasia: a pilot study. Urology. 2009;73(6):1274–8. doi:10.1016/j.urology.2008.08.461.
Levine AC, Liu XH, Greenberg PD, Eliashvili M, Schiff JD, Aaronson SA, et al. Androgens induce the expression of vascular endothelial growth factor in human fetal prostatic fibroblasts. Endocrinology. 1998;139(11):4672–8. doi:10.1210/endo.139.11.6303.
Franck-Lissbrant I, Haggstrom S, Damber JE, Bergh A. Testosterone stimulates angiogenesis and vascular regrowth in the ventral prostate in castrated adult rats. Endocrinology. 1998;139(2):451–6. doi:10.1210/endo.139.2.5683.
Lekas E, Engstrand C, Bergh A, Damber JE. Transient ischemia induces apoptosis in the ventral prostate of the rat. Urol Res. 1999;27(3):174–9.
Marshall S, Narayan P. Treatment of prostatic bleeding: suppression of angiogenesis by androgen deprivation. J Urol. 1993;149(6):1553–4.
Ku JH, Shin JK, Cho MC, Myung JK, Moon KC, Paick JS. Effect of dutasteride on the expression of hypoxia-inducible factor-1alpha, vascular endothelial growth factor and microvessel density in rat and human prostate tissue. Scand J Urol Nephrol. 2009;43(6):445–53. doi:10.3109/00365590903337896.
Haggstrom S, Torring N, Moller K, Jensen E, Lund L, Nielsen JE, et al. Effects of finasteride on vascular endothelial growth factor. Scand J Urol Nephrol. 2002;36(3):182–7. doi:10.1080/003655902320131848.
Berardinis EDAG, Busetto GM, Gentile V, Silverio FD, et al. Reduced intraoperative bleeding during transurethral resection of the prostate: evaluation of finasteride, vascular endothelial growth factor, and CD34. Curr Prostate Rep. 2005;6:123–7.
Pareek G, Shevchuk M, Armenakas NA, Vasjovic L, Hochberg DA, Basillote JB, et al. The effect of finasteride on the expression of vascular endothelial growth factor and microvessel density: a possible mechanism for decreased prostatic bleeding in treated patients. J Urol. 2003;169(1):20–3. doi:10.1097/01.ju.0000039923.75777.91.
Sutton MT, Yingling M, Vyas A, Atiemo H, Borkowski A, Jacobs SC, et al. Finasteride targets prostate vascularity by inducing apoptosis and inhibiting cell adhesion of benign and malignant prostate cells. Prostate. 2006;66(11):1194–202. doi:10.1002/pros.20444.
Jia G, Heverhagen JT, Polzer H, Jacko RV, Liang J, Zhang J, et al. Dynamic contrast enhanced magnetic resonance imaging as a biological marker to noninvasively assess the effect of finasteride on prostatic suburethral microcirculation. J Urol. 2006;176(5):2299–304. doi:10.1016/j.juro.2006.07.056.
Deering RE, Bigler SA, Brown M, Brawer MK. Microvascularity in benign prostatic hyperplasia. Prostate. 1995;26(3):111–5.
Hochberg DA, Basillote JB, Armenakas NA, Vasovic L, Shevchuk M, Pareek G, et al. Decreased suburethral prostatic microvessel density in finasteride treated prostates: a possible mechanism for reduced bleeding in benign prostatic hyperplasia. J Urol. 2002;167(4):1731–3.
Donohue JF, Sharma H, Abraham R, Natalwala S, Thomas DR, Foster MC. Transurethral prostate resection and bleeding: a randomized, placebo controlled trial of role of finasteride for decreasing operative blood loss. J Urol. 2002;168(5):2024–6. doi:10.1097/01.ju.0000028607.29093.56.
Lund L, Moller Ernst-Jensen K, Torring N, Erik Nielsen J. Impact of finasteride treatment on perioperative bleeding before transurethral resection of the prostate: a prospective randomized study. Scand J Urol Nephrol. 2005;39(2):160–2. doi:10.1080/00365590510007694.
Sandfeldt L, Bailey DM, Hahn RG. Blood loss during transurethral resection of the prostate after 3 months of treatment with finasteride. Urology. 2001;58(6):972–6.
• Hahn RG, Fagerstrom T, Tammela TL, Van Vierssen TO, Beisland HO, Duggan A, et al. Blood loss and postoperative complications associated with transurethral resection of the prostate after pretreatment with dutasteride. BJU Int. 2007;99(3):587–94. doi:10.1111/j.1464-410X.2006.06619. This study is the largest and most rigorous study examining the use of a 5ARI in men. Clinical outcomes were not convincingly improved through the use of Dutasteride
Kaplan SA, Lee JY, Meehan AG, Kusek JW, Group MR. Long-term treatment with finasteride improves clinical progression of benign prostatic hyperplasia in men with an enlarged versus a smaller prostate: data from the MTOPS trial. J Urol. 2011;185(4):1369–73. doi:10.1016/j.juro.2010.11.060.
Busetto GM, Giovannone R, Antonini G, Rossi A, Del Giudice F, Tricarico S, et al. Short-term pretreatment with a dual 5alpha-reductase inhibitor before bipolar transurethral resection of the prostate (B-TURP): evaluation of prostate vascularity and decreased surgical blood loss in large prostates. BJU Int. 2015;116(1):117–23. doi:10.1111/bju.12917.
• Zhu YP, Dai B, Zhang HL, Shi GH, Ye DW. Impact of preoperative 5alpha-reductase inhibitors on perioperative blood loss in patients with benign prostatic hyperplasia: a meta-analysis of randomized controlled trials. BMC Urol. 2015;15:47. doi:10.1186/s12894-015-0043-4. This meta-analysis of controlled trials found fairly minor effects of 5ARI but included studies with heterogeneous study designs and varied outcomes
Gormley GJ, Stoner E, Bruskewitz RC, Imperato-McGinley J, Walsh PC, McConnell JD, et al. The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group. N Engl J Med. 1992;327(17):1185–91. doi:10.1056/NEJM199210223271701.
Aminsharifi A, Salehi A, Noorafshan A, Aminsharifi A, Alnajar K. Effect of preoperative finasteride on the volume or length density of prostate vessels, intraoperative, postoperative blood loss during and after monopolar transurethral resection of prostate: a dose escalation randomized clinical trial using stereolog methods. Urol J. 2016;13(1):2562–8.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of Interest
Matthew Bruha declares no potential conflicts of interest.
Charles Welliver reports honorarium from the American Society of Andrology, a paid reviewer for BMJ and Oakstone Publishing, and a consultant for Coloplast.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Additional information
This article is part of the Topical Collection on Benign Prostatic Hyperplasia
Rights and permissions
About this article
Cite this article
Bruha, M., Welliver, C. Is There a Role for Preoperative 5 Alpha Reductase Inhibitors in Reducing Prostate Vascularity and Blood Loss?. Curr Urol Rep 18, 75 (2017). https://doi.org/10.1007/s11934-017-0730-7
Published:
DOI: https://doi.org/10.1007/s11934-017-0730-7